Introduction: Delays in the lung cancer care pathway and limited access to molecular biomarkers, targeted therapies, and immunotherapy may affect diagnosis, treatment opportunities, and survival. This study described the clinical profile, care pathway delays, biomarker testing, treatment access, and survival of patient...
Rebeca Alvarado-Prado, A. Ortiz-Barboza, Alejandro Blanco-Saborío et al.· Cureus· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.